FDA authorized first test that detected neutralizing antibodies from recent or prior SARS-CoV-2 infection
On Nov. 6, 2020, the FDA authorized the first serology test that detected neutralizing antibodies from recent or…
On Nov. 6, 2020, the FDA authorized the first serology test that detected neutralizing antibodies from recent or…
On Oct. 31, 2020, the U.S. Department of Health and Human Services and the U.S. Department of Defense…
On Oct. 28, 2020, researchers at the University of Nebraska Medical Center (UNMC) reported the results of a…
On Aug. 27, 2020, immunologists at Scripps Research, in partnership with colleagues at the IAVI Neutralizing Antibody Center,…
On Oct. 22, 2020, IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges,…
On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase…
On Oct. 19, 2020, Bio-Techne announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for…
On Oct. 19, 2020, LabCorp announced a test that provided a quantitative measurement of an individualï¾’s SARS-CoV-2 IgG…
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
On Oct. 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD)…
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
On Oct. 7, 2020, Eli Lilly announced additional details on its SARS-CoV-2 neutralizing antibody programs ï¾– including interim…
On Sept. 30, 2020, ViralClear Pharmaceuticals and Sorrento Therapeutics announced the companies were exploring the synergistic potential of…
On Sept. 23, 2020, the FDA issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care…
On Sept. 22, 2020, Oxford Immunotec announced that it had entered into an extensive research collaboration with Public…
On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVIDï¾™ for…
On Sept. 18, 2020, Roche announced the launch of its Elecsysï¾® Anti-SARS-CoV-2 S antibody test for markets accepting…
On Sept. 17, 2020, Eli Lilly and Amgen announced a global antibody manufacturing collaboration to significantly increase the…
On Sept. 16, 2020, a study by researchers at La Jolla Institute for Immunology published in the Cell,…
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
On Sept. 15, 2020, the University of Texas Health Science Center at Houston (UTHealth) announced that a study…
On Sept. 14, 2020, Meridian Bioscience announced the launch of a novel highly sensitive SARS-CoV-2 antibody pair to…
On Sept. 10, 2020, Corvus Pharmaceuticals announced updated data from its ongoing Phase 1 study investigating the potential…
On Sept. 3, 2020, ADMA Biologics announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA…